2021 Benchmark

Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.

The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.

Large R&D-based companies

84%
GSK
Projects in the pipeline: 31
Products on the market: 51
Score breakdown
Research & Development: 93%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
81%
Pfizer
Projects in the pipeline: 13
Products on the market: 116
Score breakdown
Research & Development: 77%
Responsible Manufacturing: 80%
Appropriate Access: 80%
Stewardship: 90%
68%
Johnson & Johnson
Projects in the pipeline: 14
Products on the market: 8
Score breakdown
Research & Development: 50%
Responsible Manufacturing: 80%
Appropriate Access: 72%
Stewardship: 80%
63%
Novartis
Projects in the pipeline: N/A
Products on the market: 109
Score breakdown
Research & Development: 7%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
60%
Sanofi
Projects in the pipeline: 6
Products on the market: 47
Score breakdown
Research & Development: 33%
Responsible Manufacturing: 73%
Appropriate Access: 84%
Stewardship: 60%
58%
Shionogi
Projects in the pipeline: 11
Products on the market: 8
Score breakdown
Research & Development: 70%
Responsible Manufacturing: 93%
Appropriate Access: 4%
Stewardship: 80%
57%
Otsuka
Projects in the pipeline: 4
Products on the market: 1
Score breakdown
Research & Development: 56%
Responsible Manufacturing: 43%
Appropriate Access: 60%
Stewardship: 65%
46%
MSD
Projects in the pipeline: 13
Products on the market: 19
Score breakdown
Research & Development: 47%
Responsible Manufacturing: 73%
Appropriate Access: 29%
Stewardship: 55%

Generic medicine manufacturers

71%
Aurobindo
Projects in the pipeline: N/A
Products on the market: 39
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 60%
Stewardship: 87%
69%
Abbott
Projects in the pipeline: N/A
Products on the market: 85
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 53%
Stewardship: 80%
67%
Viatris
Projects in the pipeline: N/A
Products on the market: 87
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 72%
Stewardship: 53%
63%
Fresenius Kabi
Projects in the pipeline: N/A
Products on the market: 51
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 53%
Stewardship: 80%
60%
Cipla
Projects in the pipeline: N/A
Products on the market: 59
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 40%
Stewardship: 87%
60%
Teva
Projects in the pipeline: N/A
Products on the market: 137
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 47%
Stewardship: 80%
47%
Sun Pharma
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 47%
Stewardship: 60%
20%
Alkem
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 20%
Stewardship: 0%
15%
Hainan Hailing
Projects in the pipeline: N/A
Products on the market: 43
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 20%
Appropriate Access: 20%
Stewardship: 0%
Room to improve Performance so far

Insights

  • Improvement in antimicrobial sales practices, especially from generics companies

    When sales agents’ bonuses are linked to how much antibacterial and antifungal medicine is sold, this acts as an incentive for these staff to oversell in order to increase their own pay. In 2021, more generic medicine manufacturers are taking action to combat overselling. 

    > To the analysis

  • Tech transfers are being carried out as isolated, yet valuable, initiatives

    To support the development of local manufacturing in low and middle income countries, pharma companies can invest in capacity building and technology transfers. Half of the on-patent vaccines analysed are subject to a technology transfer initiative. Very few initiatives cover any of the 148 medicines analysed. 

    > To the analysis

  • Most companies support efforts to track resistance

    To control the spread of resistance, it is important to track cases and infection rates. Most companies are engaged in surveillance to some extent: all of the eight large research-based companies evaluated, except Otsuka, and three generic medicine manufacturers, Abbott, Cipla and Viatris.

    > To the analysis

  • Slow progress on expanding product registrations to low- and middle-income countries

    Less wealthy nations often have the highest need for new medicines arriving on the market. Yet only six of the sampled on-patent medicines have been filed in ten or more of the 102 low- and middle-income countries prioritised for this analysis.

    > To the analysis


Get in touch

Back to top |